Latest News

Latest News

Bristol Members Conference 20 Jul 2018 videos available

The meeting summary together with the videos and slides of the main presentations by Prof Chris Fegan and Dr Stephen Man are now available here

Prof Chris Fegan talked to “CLL treatment – who needs treatment and how do we move from where we are to cure?” 

Dr Stephen Man talked about his research into T cells 

The photo shows Olga Janssen Prof Chris Fegan and Dr Stephen Man on the roof of the venue 'We the curious' in Bristol.

Ask Tanya Byron: I’m terrified of dying, and the thought that it nearly happened makes it difficult to breathe

Living with a long-term incurable blood cancer presents many people with enormous physical and emotional pressures. We are grateful to Professor Tanya Byron for highlighting these issues in The Times.

read article here

FDA Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

On June 8, 2018, the U.S. Food and Drug Administration (FDA) approved the use of venetoclax (VENCLEXTA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

This approval is based on data from a clinical trial evaluating venetoclax in combination with rituximab (Rituxan). The trial compared venetoclax plus rituximab with bendamustine plus rituximab in CLL patients who had received at least one prior line of therapy.